GLP-1 Receptor Agonists
GLP-1 Receptor Agonists scored 6.0 / 10 (👍 Worth trying) on the BioHarmony scale as a Peptide drug class (GLP-1 receptor agonists).
GLP-1 receptor agonists such as semaglutide, liraglutide and the dual agonist tirzepatide cut body weight 15 to 21% and HbA1c by 1 to 2 points, and semaglutide reduced major cardiovascular events 20% in the 17,604-person SELECT trial. Weight is largely regained after stopping, and the drugs carry GI side effects and a rodent thyroid tumour warning.
Terminology
The GLP-1 field is thick with drug brand names, hormone abbreviations and trial acronyms, and the distinctions decide how you read every number below. The single most important one is that these drugs are chronic therapies rather than courses, because that reframes weight regain after stopping as expected behaviour rather than failure.
A second is the difference between a single GLP-1 agonist and a dual agonist like tirzepatide that also hits the GIP receptor, since that is the main reason one drug in the class outperforms another on weight. The trial names matter too, because each landmark study answers a different question, from weight to heart attacks to kidney failure.
Here is the vocabulary that recurs throughout the report and why each term changes the interpretation of the evidence.
- GLP-1: Glucagon-like peptide-1, a hormone released by the gut after eating that stimulates insulin, suppresses glucagon and reduces appetite.
- GIP: Glucose-dependent insulinotropic polypeptide, a second incretin hormone; tirzepatide targets both GIP and GLP-1.
- Incretin: The family of gut hormones, including GLP-1 and GIP, that amplify insulin release after a meal.
- HbA1c: Glycated haemoglobin, a marker of average blood glucose over roughly three months, used to judge diabetes control.
- MACE: Major adverse cardiovascular events, typically cardiovascular death, non-fatal heart attack and non-fatal stroke combined.
- CVOT: Cardiovascular outcome trial, a large study designed to measure hard heart endpoints rather than markers.
- MTC and MEN 2: Medullary thyroid carcinoma and multiple endocrine neoplasia type 2, the thyroid conditions that contraindicate this class.
- NAION: Non-arteritic anterior ischemic optic neuropathy, a sudden optic-nerve injury reported as an emerging safety signal.
- Lean mass: Non-fat body tissue, mostly muscle, a portion of which is lost during rapid weight reduction.
Semaglutide reduced major adverse cardiovascular events by 20% over a mean of 40 months in 17,604 people with cardiovascular disease and obesity but no diabetes. Lincoff and colleagues, New England Journal of Medicine (SELECT)
How do you take GLP-1 Receptor Agonists?
Dosing & Protocols
Dosing information is summarized from published research and community reports. This is not a prescribing guide. Consult a healthcare provider before starting any protocol.
View 2 routes and 3 protocols
Routes & Forms
| Route | Form | Clinical Range | Community Range |
|---|---|---|---|
| Subcutaneous injection | Prefilled pen or vial, weekly (semaglutide, dulaglutide, tirzepatide) or daily (liraglutide, exenatide) | Semaglutide 0.25 to 2.4 mg weekly; tirzepatide 2.5 to 15 mg weekly; liraglutide 0.6 to 3.0 mg daily Every agent starts low and steps up every 4 weeks to blunt nausea before reaching the therapeutic dose | Compounded and telehealth dosing tracks the label ranges, often with slower personal titration |
| Oral | Oral semaglutide tablet (Rybelsus), taken fasting with a sip of water | 3 mg, 7 mg, 14 mg once daily; a 25 mg weight-management tablet is under review Absorption is low and fragile, which is why the fasting-and-wait ritual matters | Used by people who will not inject, accepting somewhat lower average weight loss |
Protocols
Semaglutide 2.4 mg weekly for weight management Clinical
- Dose
- Titrate 0.25 to 2.4 mg
- Frequency
- Once weekly
- Duration
- Indefinite while benefit continues
The Wegovy schedule. Reaches 2.4 mg at week 16 and produced about 15% mean weight loss over 68 weeks.
Tirzepatide 15 mg weekly for weight management Clinical
- Dose
- Titrate 2.5 to 15 mg
- Frequency
- Once weekly
- Duration
- Indefinite while benefit continues
The Zepbound schedule. Highest weight loss of the class at up to 21% over 72 weeks, and the highest GI burden.
Semaglutide up to 2.0 mg weekly for type 2 diabetes Clinical
- Dose
- Titrate 0.25 to 2.0 mg
- Frequency
- Once weekly
- Duration
- Indefinite
The Ozempic schedule, dosed for glucose control and cardiovascular risk rather than maximum weight loss.
How this score is calculated →
What are the benefits of GLP-1 Receptor Agonists?
Upside contribution: 3.00
| Dimension | Weight | Band | Visual | Weighted |
|---|---|---|---|---|
| Efficacy | 25% | Exceptional | 1.125 | |
| Breadth | 15% | Strong | 0.600 | |
| Evidence | 25% | Exceptional | 1.150 | |
| Speed | 10% | Strong | 0.350 | |
| Durability | 10% | Moderate | 0.250 | |
| Bioindividuality | 15% | Strong | 0.525 | |
| Total | 4.000 | |||
| Baseline offset (constant) | −1.000 | |||
| Effective upside contribution | 3.000 |
Dimensions are shown as a band rather than a decimal because repeat scoring of the same evidence moves a single dimension by up to 1 point. Hover or long-press a band to see the value it was scored at.
Upside Rationale
The upside of GLP-1 receptor agonists is unusually broad and unusually well proven for a drug class. The headline is weight and glucose, but the reason this class scores where it does is that the benefits carry through to hard outcomes: fewer cardiovascular events, slower kidney decline, and better sleep apnoea, each demonstrated in a dedicated randomised trial.
A class meta-analysis of 60,080 people confirmed these effects at scale (Sattar et al. 2021). What holds the upside back from the very top is durability, since most of the weight returns after stopping, and body composition, since a meaningful share of the loss is muscle.
The dimensions below separate the size of the effect, its breadth, and the strength of the evidence, because this class is strong on all three at once, which is rare.
Efficacy (Exceptional): GLP-1 receptor agonists produce the largest and most reliable pharmacological weight and glucose effects available, with semaglutide cutting body weight about 15% and tirzepatide up to 20.9% against placebo (Jastreboff et al. 2022), and HbA1c falling 1 to 2 percentage points in type 2 diabetes.
The effect is dose-ordered, consistent across large trials, and translates into hard outcomes rather than markers alone. It falls short of a perfect score only because the newer agents deliver the top numbers while older ones like exenatide are meaningfully weaker, so class-average efficacy sits below the tirzepatide ceiling.
Breadth of Benefits (Strong): Few drug classes touch as many systems with proven endpoints. Beyond weight and glucose, GLP-1 receptor agonists reduce major cardiovascular events (Marso et al. 2016), slow diabetic kidney disease, and cut obstructive sleep apnoea severity.
They also improve liver histology in steatohepatitis (Malhotra et al. 2024), and emerging research reaches into addiction and neurodegeneration, though those remain unproven. The breadth is genuine rather than marketing, since each major claim rests on its own trial.
The score is not higher only because much of the breadth is downstream of weight loss rather than independent action, and because several of the newest indications are agent-specific rather than true class effects.
Evidence Quality (Exceptional): This is the strongest evidence base of any intervention in the metabolic space. A meta-analysis pooled eight cardiovascular outcome trials and 60,080 participants and found consistent reductions in cardiovascular events, mortality and kidney outcomes (Sattar et al. 2021).
That sits on top of dozens of phase 3 weight and glucose trials and clinical use stretching back to FDA approval of exenatide, the first drug in the class, in 2005. The main deductions are that nearly every trial is funded and run by the two manufacturers, and that long-term safety past a few years is still accumulating.
Even after those adjustments, the depth, size and hard-endpoint focus of the data put this class near the top of the scale.
Speed of Onset (Strong): Appetite suppression and glucose lowering begin within the first week or two, even at the sub-therapeutic starting doses (Wilding et al. 2021), so people notice reduced hunger quickly.
Full weight loss is another matter, building over 6 to 18 months because the dose is stepped up in stages to keep nausea manageable. That deliberately slow titration is why this scores in the middle rather than high: the mechanism acts fast, but the complete effect takes a year or more to express, which is slower to finish than acute interventions.
Durability (Moderate): Durability is the class's clearest weakness. The drugs work while present and stop working when cleared, and the STEP 1 extension showed people regaining roughly two-thirds of their lost weight within a year of stopping, with cardiometabolic gains reversing toward baseline (Wilding et al. 2022).
This is a chronic therapy, not a course, and the benefit is contingent on continued use. The score sits low because the effect is not self-sustaining. What keeps it off the floor is that the benefits are fully maintained for as long as the drug is taken, which is different from tolerance or fade.
Bioindividuality Upside (Strong): Response is broad rather than concentrated in a lucky subgroup: most people on the therapeutic doses clear a meaningful weight-loss threshold, with the majority losing at least 10% in the obesity trials (Wilding et al. 2021).
A minority are weak responders, and some cannot tolerate the gut side effects long enough to reach the effective dose, so individual odds are good but not guaranteed. The score reflects that a typical person has a high chance of a worthwhile result, tempered by real variation in both efficacy and tolerability that no biomarker yet predicts well.
What are the risks & downsides of GLP-1 Receptor Agonists?
Downside contribution: 2.23 (safety risks weighted extra)
| Dimension | Weight | Band | Visual | Weighted |
|---|---|---|---|---|
| Safety | 30% | Moderate | 0.780 | |
| Side effects | 15% | Moderate | 0.450 | |
| Cost premium | 5% | High | 0.175 | |
| Effort | 5% | Moderate | 0.130 | |
| Opportunity | 5% | Moderate | 0.130 | |
| Dependency | 15% | Moderate | 0.510 | |
| Reversibility | 25% | Low | 0.500 | |
| Total | 2.675 | |||
| Harm subtotal × 1.4 | 3.136 | |||
| Opportunity subtotal × 1.0 | 0.435 | |||
| Combined downside | 3.571 | |||
| Baseline offset (constant) | −1.340 | |||
| Effective downside penalty | 2.231 |
Dimensions are shown as a band rather than a decimal because repeat scoring of the same evidence moves a single dimension by up to 1 point. Hover or long-press a band to see the value it was scored at.
Cost premium: premium over the cheapest legitimate route, not price.
Downside Rationale
The dominant downside of GLP-1 receptor agonists is not acute danger but the combination of frequent gut side effects, a chronic commitment, muscle loss, and cost. No common catastrophic effect has emerged across enormous trial populations: the boxed thyroid warning is rodent-derived and unconfirmed in humans, and pancreatitis is rare.
What people actually contend with is nausea and other gastrointestinal symptoms, the knowledge that stopping means regaining most of the weight, the erosion of lean mass without training, and a price that is high wherever insurance does not cover it. A handful of genuine safety signals, including gallbladder disease and an emerging optic-nerve association, deserve monitoring rather than alarm.
The dimensions below separate demonstrated harm from tolerability and from cost, because for this class those are three different problems.
Safety Risk (Moderate): No common catastrophic harm has surfaced despite trial populations in the tens of thousands, which is reassuring for a class used this widely. The boxed warning for thyroid C-cell tumours comes from rodents and is unconfirmed in humans, though it firmly contraindicates use in medullary thyroid cancer or MEN 2.
Real but uncommon risks include pancreatitis, gallbladder and biliary disease that rises with dose (He et al. 2022), hypoglycemia when combined with insulin or sulfonylureas, and an emerging, unproven optic-nerve association (Hathaway et al. 2024).
The score reflects a class that is generally safe but carries several genuine cautions and a not-yet-mature long-term record.
Side Effect Profile (Moderate): Gastrointestinal side effects are common, dose-related and often the reason people quit. Nausea, vomiting, diarrhea and constipation appear in a large fraction of users during titration and ease over time (Wilding et al. 2021), and slow dose escalation is the main tool to manage them.
Delayed gastric emptying can cause reflux and, rarely, retained stomach contents that matter around anaesthesia. These are frequent and unpleasant rather than dangerous for most people, which is why this scores mid-range: the burden is real, tolerable for the majority, and worst early rather than sustained.
Financial Cost (High): Cost is a serious barrier where insurance does not cover it. US list prices run roughly $500 to $1,300 per month depending on the agent and indication, and while insurance, compounding pharmacies and telehealth services lower that for many people, coverage for weight-loss indications is inconsistent and often denied.
Because the therapy is effectively indefinite, the cumulative cost is large. The score reflects an expensive commitment whose real out-of-pocket price varies enormously by channel and by whether the prescription is for diabetes or weight.
Time/Effort Burden (Moderate): The dosing itself is light: a weekly or daily injection with a prefilled pen, or a daily oral tablet, is easy to fit into a routine. The effort sits around it.
A titration schedule runs several weeks to months, oral semaglutide demands strict fasting timing, and getting a worthwhile result requires pairing the drug with resistance training and adequate protein to protect muscle.
Add the periodic monitoring and prescription logistics, and the burden is modest but not zero, which places this in the middle of the range rather than at the easy end.
Opportunity Cost (Moderate): The main opportunity cost is that a drug which suppresses appetite can quietly substitute for the protein intake, resistance training and sleep that determine whether the weight lost is fat or muscle. Relying on the injection alone tends to cost lean mass and leaves the underlying habits unaddressed, so weight often returns fast on stopping.
There is no exercise interference in the pharmacological sense, and the drug stacks well with lifestyle change when used deliberately. The score reflects a real risk of the drug replacing rather than supporting the behaviours that make the result durable.
Dependency/Withdrawal (Moderate): This is functional dependency rather than addiction, and it should be assumed rather than hoped against.
GLP-1 receptor agonists produce no craving, tolerance or withdrawal syndrome, but they supply an appetite signal continuously, and when that supply stops the signal stops with it, which is why most weight returns after discontinuation (Wilding et al. 2022).
Anyone starting should plan on indefinite use or plan the maintenance strategy first. The score is elevated because the benefit is contingent on continued dosing, not because the drugs are habit-forming in the addictive sense.
Reversibility (Low): Stopping is pharmacologically clean. These are peptides that clear the body without leaving a structural change behind, with no taper required and no permanent receptor damage described. The weight regain that follows is a durability problem scored above, not a reversibility harm, and is not double-counted here.
The one caveat is that muscle lost during rapid weight loss does not automatically return, so body composition after a cycle can be worse than before it unless training rebuilds the lost tissue. On the narrow question of clean discontinuation, this class scores well.
One year after withdrawal of once-weekly semaglutide and lifestyle intervention, participants regained two-thirds of their prior weight loss, with similar reversal of cardiometabolic improvements. Wilding and colleagues, Diabetes Obesity and Metabolism
Is GLP-1 Receptor Agonists worth it?
GLP-1 receptor agonists are the best-evidenced pharmacological route to weight and glucose control that exists, and the honest verdict is that they are excellent for the right person and a lifelong commitment for everyone who uses them.
The weight loss is large, the glucose control is strong, and the cardiovascular and kidney outcome data is something almost no other metabolic intervention can claim (Lincoff et al. 2023).
Against that sit frequent gut side effects, a real cost, muscle loss without training, and the fact that stopping means regaining most of the weight. This is not a shortcut to try casually. It is a serious, effective therapy for defined conditions, best used with a plan for training, protein and long-term maintenance.
✅ Best for: People with type 2 diabetes who want strong glucose control with cardiovascular and kidney protection built in. People with class 2 or class 3 obesity for whom lifestyle change alone has not worked and who can commit to long-term therapy. People with established cardiovascular disease and obesity, the SELECT population, who gain event reduction independent of diabetes.
People with obesity and obstructive sleep apnoea, where tirzepatide has a dedicated indication. People willing to pair the drug with resistance training and adequate protein so the weight lost is fat rather than muscle.
❌ Avoid if: You have a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2, an absolute contraindication for the class. You have had pancreatitis or active gallbladder disease, which the class can worsen. You are pregnant, trying to conceive or breastfeeding, since safety is not established and the drug must be stopped before conception.
You use mealtime insulin or a sulfonylurea without a plan to adjust them, given the hypoglycemia risk. You want a short-term fix rather than an ongoing therapy, because the weight returns once you stop.
What is GLP-1 Receptor Agonists best for?
The overall BioHarmony score reflects the intervention's primary evidence profile. These subratings are independent assessments per use case.
Blood Sugar / Glycemic Control: 8.0/10
Score: 8.0/10GLP-1 receptor agonists are among the most effective non-insulin glucose-lowering drugs available, cutting HbA1c by roughly 1 to 2 percentage points across the SUSTAIN and LEADER programmes with a low intrinsic hypoglycemia risk because insulin release is glucose-dependent (Marso et al. 2016). A class meta-analysis of cardiovascular outcome trials confirmed durable glycemic benefit alongside outcome protection across tens of thousands of people with type 2 diabetes (Sattar et al. 2021). The score stops short of the top only because the drugs are injectable or awkwardly oral and expensive, and because hypoglycemia does appear when they are combined with insulin or a sulfonylurea. For glucose control in type 2 diabetes, this is a first-line-grade effect with an unusually strong outcome record behind it.
Body Composition / Fat Loss: 7.5/10
Score: 7.5/10This class produces the largest sustained pharmacological weight loss ever brought to market, about 15% mean reduction on semaglutide 2.4 mg over 68 weeks (Wilding et al. 2021) and up to 20.9% on tirzepatide 15 mg over 72 weeks (Jastreboff et al. 2022). The honest limit is body composition: roughly a quarter to 40% of the weight lost is lean mass, so the number on the scale overstates the fat lost unless resistance training and high protein intake protect muscle. Weight is also largely regained after stopping, which is a durability problem rather than an efficacy one. For fat loss while on the drug, nothing else in the pharmacological toolkit is close.
Metabolic Health: 7.5/10
Score: 7.5/10Beyond weight and glucose, GLP-1 receptor agonists move the whole metabolic panel in the right direction: blood pressure, triglycerides, waist circumference and inflammatory markers all improved alongside weight across the STEP and SURMOUNT programmes (Wilding et al. 2021). Emerging data extend the reach to metabolic dysfunction-associated steatohepatitis, where semaglutide improved liver histology in phase 2 and 3 work. Most of these gains are downstream of the weight loss rather than independent drug effects, which is why the score sits high but not at the ceiling. For someone whose metabolic syndrome is driven by excess adiposity and glucose dysregulation, this class addresses several of the root levers at once rather than treating each marker separately.
Cardiovascular: 7.0/10
Score: 7.0/10GLP-1 receptor agonists are the rare weight and glucose drugs with hard cardiovascular outcome data, not just marker improvement. Semaglutide reduced major adverse cardiovascular events 20% in the 17,604-person SELECT trial of people with established heart disease and obesity but no diabetes (Lincoff et al. 2023), and a class meta-analysis found a 14% reduction in major events across the diabetes outcome trials (Sattar et al. 2021). That evidence base is what separates this class from almost every other metabolic intervention. The score is held below the top by an increase in resting heart rate on drug and by the fact that not every agent has shown the same benefit.
Kidney Function: 6.0/10
Score: 6.0/10Kidney protection is now a proven, indication-level benefit rather than an inference. In the FLOW trial, semaglutide cut the risk of major kidney disease events and death 24% in people with type 2 diabetes and chronic kidney disease, stopping early for efficacy (Perkovic et al. 2024), and the class meta-analysis showed consistent reductions in worsening kidney function (Sattar et al. 2021). The score sits mid-range rather than higher because the strongest evidence is in the diabetic kidney population, and because severe vomiting or diarrhea can transiently injure the kidneys through dehydration. For diabetic chronic kidney disease specifically, this is one of the few drug classes that changes the trajectory.
Healthspan: 5.5/10
Score: 5.5/10The healthspan case for GLP-1 receptor agonists is unusually concrete for a weight drug: losing 15 to 20% of body weight while cutting cardiovascular events, kidney decline and sleep apnoea severity together addresses several of the biggest drivers of disability at once. Tirzepatide reduced obstructive sleep apnoea severity substantially in SURMOUNT-OSA (Malhotra et al. 2024). The score is capped in the middle because none of this is a longevity endpoint, the muscle-loss question shadows any healthspan claim in older adults, and the benefit continues only while treatment does. Treat it as strong risk-factor modification with real downstream payoff, not as a proven extension of healthy lifespan.
Liver / Detoxification: 5.0/10
Score: 5.0/10Liver fat and inflammation improve reliably with the weight loss this class produces, and semaglutide has now shown histological improvement in metabolic dysfunction-associated steatohepatitis in controlled trials, which is a genuine organ-level benefit rather than a marker shift. The score sits at the boundary because the strongest liver data is newer and agent-specific, and because the effect is largely mediated by weight loss rather than a direct hepatic mechanism. A falling ALT over a few months is the cheapest at-home proxy for the change. For fatty liver driven by obesity, this class is one of the more effective pharmacological options currently available.
| Use Case | Score | Summary |
|---|---|---|
| ○ Sleep Quality | 4.5 | Sleep is one of the stronger secondary wins, because tirzepatide substantially reduced obstructive sleep apnoea severity in the dedicated SURMOUNT-OSA trial (Malhotra et al. 2024), and weight loss improves apnoea regardless of the drug. The score is held below the primary use cases because the benefit is specific to weight-related sleep-disordered breathing rather than sleep quality in general. |
| ○ Anti-Inflammatory | 3.5 | Inflammatory markers such as C-reactive protein fall alongside weight in the STEP and SURMOUNT trials, and there is mechanistic interest in direct GLP-1 receptor effects on immune cells. The effect is real but largely downstream of fat loss rather than a dedicated anti-inflammatory action, so the score stays moderate. |
| ○ Hormonal / Endocrine | 3.0 | Large weight loss can restore ovulatory cycles in polycystic ovary syndrome and improve testosterone in men with obesity, so there are real downstream endocrine benefits. These follow from fat loss rather than a direct hormonal mechanism, which keeps the score modest. |
| ○ Fertility (Female) | 3.0 | By restoring ovulatory cycles in polycystic ovary syndrome, weight loss on this class can improve fertility, but the drugs must be stopped before conception because pregnancy safety is not established. |
| ○ Chronic Pain Management | 3.0 | Weight loss reduces load-related joint pain and there is early interest in GLP-1 effects on inflammatory and neuropathic pain, but the pain benefit is currently secondary to the weight change rather than a proven direct effect. |
| ○ Substance Use / Addiction Support | 3.0 | There is genuine and growing signal that GLP-1 receptor agonists blunt reward-driven consumption of alcohol and other substances, with trials underway, but no approved indication and no confirmed effect size yet. Promising, not proven. |
Frequently Asked Questions
How much weight do GLP-1 drugs actually cause people to lose?
Mean weight loss is about 15% over 68 weeks on semaglutide 2.4 mg (Wilding et al. 2021) and up to 20.9% over 72 weeks on tirzepatide 15 mg (Jastreboff et al. 2022), against 2 to 3% on placebo. Older agents like liraglutide and exenatide produce less, closer to 5 to 8%. The catch is that roughly two-thirds returns within a year of stopping, so these numbers hold only while you keep taking the drug.
What is the difference between semaglutide and tirzepatide?
Semaglutide activates the GLP-1 receptor alone, while tirzepatide activates both the GIP and GLP-1 receptors, and in head-to-head and cross-trial data tirzepatide produces more weight loss, up to about 21% versus 15% (Jastreboff et al. 2022). Both lower blood sugar strongly and both carry similar GI side effects. Semaglutide has the larger cardiovascular and kidney outcome dataset so far, which matters if outcome protection, not just weight, is the goal.
Do GLP-1 drugs protect the heart and kidneys, or just cause weight loss?
They do both, and the outcome data is the class's strongest feature. Semaglutide cut major cardiovascular events 20% in people with heart disease and obesity but no diabetes (Lincoff et al. 2023), and reduced kidney disease progression and death 24% in diabetic chronic kidney disease (Perkovic et al. 2024). A class meta-analysis confirmed lower cardiovascular events, mortality and kidney outcomes across agents. Few metabolic interventions have this level of hard-endpoint evidence.
What are the side effects of GLP-1 receptor agonists?
Nausea, vomiting, diarrhea and constipation are the most common, all dose-related and usually worst during titration before easing (Wilding et al. 2021). Slow dose escalation is the main tool to limit them. Less common concerns include gallbladder disease, which rises with higher doses (He et al. 2022), rare pancreatitis, and lean-mass loss. Most people tolerate the drugs, but a meaningful minority stop because of gut symptoms.
Is the thyroid cancer warning on GLP-1 drugs a real risk?
The boxed warning comes from rodent studies where GLP-1 agonists caused thyroid C-cell tumours, and human relevance is unconfirmed, with large trials and registries not showing a clear increase. The practical rule is firm anyway: anyone with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2 should not use the class, because that is the population where the theoretical risk concentrates. For everyone else it remains a labelled caution rather than a demonstrated human harm.
What happens when you stop taking a GLP-1 drug?
Most of the lost weight returns. In the STEP 1 extension, people regained about two-thirds of their lost weight within a year of stopping semaglutide, and the blood-pressure and lipid improvements reversed toward baseline (Wilding et al. 2022). This is functional, not addictive: the drug supplies an appetite signal that stops when the drug clears. Treat GLP-1 therapy as an ongoing commitment, or plan the maintenance strategy, including training and protein, before starting.
How fast do GLP-1 drugs start working?
Appetite suppression and glucose lowering begin within the first week or two, even at the low starting doses used to limit nausea (Wilding et al. 2021). Weight loss then builds over months as the dose steps up, reaching its full effect only after 6 to 18 months rather than in the first month. The slow schedule is deliberate: escalating too quickly worsens the gut side effects without adding benefit.
Will I lose muscle on a GLP-1 drug?
Yes, some. Across body-composition studies roughly a quarter to 40% of the weight lost on this class is lean tissue, which is typical of rapid weight loss generally rather than unique to these drugs. The countermeasures are within your control: resistance training two or three times a week and protein intake around 1.6 grams per kilogram protect most of the muscle. Older adults are the group most exposed, so the training and protein matter more with age.
What could change GLP-1 Receptor Agonists's score?
BioHarmony scores are living assessments. New research, regulatory changes, or personal context can shift the score up or down. These are the most likely scenarios that would change this intervention's rating.
The most plausible moves in this score come from long-term safety maturing and from the muscle and durability questions being answered. A clean multi-year safety record that dissolves the thyroid and optic-nerve signals, combined with better maintenance strategies that blunt post-stop regain, would lift Safety and Durability together and could push the class into Strong recommend territory.
Running the other way, a confirmed causal optic-nerve harm or a clear muscle-loss disadvantage in older adults would cut Safety and Efficacy at once. The nearer-term swing factors are oral and generic agents lowering cost, and dedicated addiction or neuroprotection trials reading out.
| Scenario | Dimension shifts | New Score |
|---|---|---|
| Long-term safety matures clean and maintenance blunts regain | Durability 2.5 to 3.5, Safety 2.6 to 2.2, confidence stays High | 6.9 / 10 👍 Worth trying |
| Low-cost generics and oral agents make the class widely affordable | Cost 3.5 to 2.5, Effort 2.6 to 2.3 | 6.4 / 10 👍 Worth trying |
| Addiction or neuroprotection indications are proven in trials | Breadth 4.0 to 4.4, Evidence 4.6 to 4.7 | 6.3 / 10 👍 Worth trying |
| The optic-nerve signal is confirmed causal in prospective data | Safety 2.6 to 3.4, confidence unchanged | 5.4 / 10 ⚖️ Neutral |
| Muscle-loss disadvantage in older adults is clearly demonstrated | Efficacy 4.5 to 4.1, Safety 2.6 to 3.0 | 5.3 / 10 ⚖️ Neutral |
| A serious long-term class safety finding emerges at scale | Safety 2.6 to 3.8, Evidence 4.6 to 4.2 | 4.6 / 10 ⚖️ Neutral |
📊 How BioHarmony Scoring Works
GLP-1 receptor agonists upside total 3.00, downside total 2.23, giving a net of +0.77 and a score of 6.0–6.5/10.Every intervention is rated 1 to 5 on six upside dimensions and seven downside dimensions, then weighted. A score of 5.0 out of 10 means the upside and the downside cancel out, not that the intervention is average. Harm-type downsides carry a 1.4 multiplier because a health risk is not interchangeable with a cost or an inconvenience; cost, effort and opportunity cost count at face value.| Upside dimension | Weight | GLP-1 receptor agonists | |---|---|---| | Efficacy | 25% | Exceptional | | Breadth of benefits | 15% | Strong | | Evidence quality | 25% | Exceptional | | Speed of onset | 10% | Strong | | Durability | 10% | Moderate | | Bioindividuality | 15% | Strong || Downside dimension | Weight | GLP-1 receptor agonists | |---|---|---| | Safety risk | 30% | Moderate | | Side effect profile | 15% | Moderate | | Financial cost | 5% | High | | Time and effort | 5% | Moderate | | Opportunity cost | 5% | Moderate | | Dependency | 15% | Moderate | | Reversibility | 25% | Low || Tier | Range | Meaning | |---|---|---| | ✅ Top-tier | 8.8 to 10.0 | Worth building a routine around | | 💪 Strong recommend | 7.0 to 8.7 | Clear net benefit for most people | | 👍 Worth trying | 5.8 to 6.9 | Favourable odds, worth a personal test | | ⚖️ Neutral | 4.5 to 5.7 | Upside and downside roughly cancel | | ⚠️ Caution | 3.0 to 4.4 | Downside usually wins | | 🚫 Skip | 0.0 to 2.9 | Not worth it |
This report is informational and is not medical advice. GLP-1 receptor agonists are prescription drugs with real risks and contraindications. Nothing here is a recommendation to start, stop or change any medication. Talk to your own clinician before making any change to treatment.
BioHarmony Engine v2.0
Key Evidence Sources
- Wilding et al. 2021, New England Journal of Medicine: STEP 1 trial of once-weekly semaglutide 2.4 mg in 1,961 adults with overweight or obesity. The landmark obesity trial for semaglutide. Mean body weight fell 14.9% at 68 weeks against 2.4% on placebo, a treatment difference of 12.4 percentage points (95% CI -13.4 to -11.5), with improvements in waist, blood pressure and lipids. Sponsor Novo Nordisk.
- Jastreboff et al. 2022, New England Journal of Medicine: SURMOUNT-1 trial of tirzepatide in 2,539 adults with obesity. The magnitude benchmark for the class. Weight change at 72 weeks was 15.0% on 5 mg, 19.5% on 10 mg and 20.9% on 15 mg, against 3.1% on placebo. Tirzepatide is a dual GIP and GLP-1 receptor agonist. Sponsor Eli Lilly.
- Lincoff et al. 2023, New England Journal of Medicine: SELECT trial of semaglutide in 17,604 people with cardiovascular disease and obesity without diabetes. The trial that turned an obesity drug into a cardiovascular drug. Semaglutide 2.4 mg reduced major adverse cardiovascular events 20% over a mean 40 months (hazard ratio 0.80, 95% CI 0.72 to 0.90) in people with no diabetes. Sponsor Novo Nordisk.
- Marso et al. 2016, New England Journal of Medicine: SUSTAIN-6 cardiovascular outcomes trial of semaglutide in 3,297 people with type 2 diabetes. First cardiovascular outcome signal for semaglutide. Major adverse cardiovascular events fell 26% (hazard ratio 0.74, 95% CI 0.58 to 0.95), driven by fewer non-fatal strokes and heart attacks, though retinopathy complications rose. Sponsor Novo Nordisk.
- Marso et al. 2016, New England Journal of Medicine: LEADER cardiovascular outcomes trial of liraglutide in 9,340 people with type 2 diabetes. The trial that established cardiovascular benefit for the class. Liraglutide cut major adverse cardiovascular events 13% and cardiovascular death 22% over a median 3.8 years. The first GLP-1 outcome trial to show a mortality benefit. Sponsor Novo Nordisk.
- Sattar et al. 2021, Lancet Diabetes and Endocrinology: systematic review and meta-analysis of GLP-1 receptor agonist cardiovascular, mortality and kidney outcomes. The class-level synthesis across eight trials and 60,080 participants. GLP-1 receptor agonists reduced major adverse cardiovascular events 14%, all-cause mortality 12% and kidney outcomes 21%, with consistent benefit across agents. The strongest single argument for treating this as a class effect.
- Perkovic et al. 2024, New England Journal of Medicine: FLOW trial of semaglutide for chronic kidney disease in 3,533 people with type 2 diabetes. The dedicated kidney outcome trial, stopped early for efficacy. Semaglutide reduced major kidney disease events and death 24% (hazard ratio 0.76, 95% CI 0.66 to 0.88) in type 2 diabetes with chronic kidney disease. Sponsor Novo Nordisk.
- Malhotra et al. 2024, New England Journal of Medicine: SURMOUNT-OSA trials of tirzepatide for obstructive sleep apnoea in obesity. The sleep-apnoea indication trial. Tirzepatide reduced the apnoea-hypopnoea index by roughly 25 to 29 events per hour, far beyond placebo, and improved blood pressure and inflammatory markers in adults with moderate to severe obstructive sleep apnoea and obesity. Sponsor Eli Lilly.
- Wilding et al. 2022, Diabetes Obesity and Metabolism: STEP 1 trial extension measuring weight regain after semaglutide withdrawal. The durability reality check. One year after stopping semaglutide and lifestyle support, participants regained two-thirds of the weight they had lost and cardiometabolic improvements reversed toward baseline. The clearest evidence that this class is a chronic therapy. Sponsor Novo Nordisk.
- He et al. 2022, JAMA Internal Medicine: systematic review and meta-analysis of GLP-1 receptor agonist use and gallbladder and biliary disease. The gallbladder safety signal. Across 76 randomised trials and 100,000 participants, GLP-1 receptor agonists raised the risk of gallbladder or biliary disease, with the effect larger at higher doses and longer duration and for weight loss rather than diabetes indications.
- Hathaway et al. 2024, JAMA Ophthalmology: risk of non-arteritic anterior ischemic optic neuropathy in patients prescribed semaglutide. The emerging optic-nerve signal. A retrospective cohort found a higher hazard of non-arteritic anterior ischemic optic neuropathy among semaglutide-prescribed patients, an association that is not proven causal and is being investigated. Included as an open safety question, not a settled harm.
What does the evidence say about GLP-1 Receptor Agonists?
Evidence on this intervention is summarized across three complementary streams: contemporary clinical research, pre-RCT-era pharmacology and observational use, and the traditional medical systems that documented it first. Convergence across streams signals higher confidence; divergence is surfaced honestly.
Modern Clinical Research
Confidence: High
Citations: Wilding 2021, Jastreboff 2022, Lincoff 2023, Marso 2016, Sattar 2021, Perkovic 2024
Pre-RCT-Era Pharmacology and Use
Confidence: Medium
Citations: Marso 2016, Perkovic 2024
Holistic Evidence for GLP-1 Receptor Agonists
The historical record and the modern trials point the same way: two decades of diabetes use predicted the glucose and cardiovascular benefits that the large outcome trials later confirmed. Where the older experience adds caution rather than reassurance is durability and body composition, both of which only became pressing once the class moved from glucose control into mass-market weight loss.
What to Track If You Try This
These are the data points that matter most while running a 30-day Experiment with this intervention.
How to read this section
- Pre
- Test or score before starting the protocol. Anchors a baseline.
- During
- Track while running the protocol so you can see if anything is changing.
- Post
- Re-test after a full cycle to confirm the change held.
- Up
- The marker should rise. For most positive outcomes, that is a good sign.
- Down
- The marker should fall. For most positive outcomes, that is a good sign.
- Stable
- The marker should hold steady. Big swings in either direction are a yellow flag.
- Watch
- Direction depends on dose, timing, and your baseline. Pay close attention to the trend.
- N/A
- No expected direction. The entry is there to anchor a baseline reading.
- Primary
- The Pulse dimension most likely to shift. Track this first.
- Secondary
- Also relevant, but a smaller or less consistent shift. Track if Primary is unclear.
Bloodwork to Order
Open These Markers In Your Dashboard
- HbA1c Pre | Expected Down
- Fasting Glucose During | Expected Down
- Triglycerides During | Expected Down
- ALT During | Expected Down
- Lipase During | Expected Watch
- Blood Pressure During | Expected Down
Pulse Dimensions to Watch
- Body During | Expected Down | Primary
- Energy During | Expected Watch | Secondary
- Calm During | Expected Watch | Tertiary
Subjective Signals (Daily Voice Card)
- Appetite and fullness between meals Scale 1-5 | During | Expected Down
- Nausea in the day or two after the dose Scale 1-5 | During | Expected Watch
- Protein intake and resistance training consistency Scale 1-5 | During | Expected Up
- Strength and gym performance holding steady Scale 1-5 | During | Expected Watch
Red Flags: Stop and Consult
- Severe upper abdominal pain radiating to the back, with or without vomiting: stop and seek care, since that pattern needs a pancreatitis check.
- A lump in the neck, hoarseness or trouble swallowing: get it evaluated, because the class carries a thyroid C-cell tumour warning.
- Any personal or family history of medullary thyroid cancer or MEN 2: do not use, per the boxed contraindication.
- Shakiness, sweating or confusion in anyone also using insulin or a sulfonylurea: treat the low blood sugar and get those doses reviewed.
- Severe or persistent vomiting or diarrhea with signs of dehydration: stop and seek care, since dehydration can injure the kidneys.
- Losing more than roughly 1% of body weight per week, or noticeably losing strength: intake is too low to preserve muscle.
- New or worsening vision loss: get an urgent eye assessment, because an optic-nerve signal has been reported and not yet explained.
Other interventions for Blood Sugar
See all ratings →📊 How BioHarmony scoring works
BioHarmony translates a weighted expected-value calculation into a reader-facing 0–10 score. Tier bands: Skip 0–2.9, Caution 3.0–4.4, Neutral 4.5–5.7, Worth Trying 5.8–6.9, Strong Recommend 7.0–8.7, Top-tier 8.8–10.0.
Harm-type downsides (safety risk, side effects, reversibility, dependency) carry a 1.4× precautionary multiplier. Harm weighs more than benefit. Opportunity-type downsides (financial cost, time/effort, opportunity cost) are subtracted at face value.
Use case subratings are independent assessments of how well the intervention addresses specific health goals. They are not components of the overall score. Each subrating reflects the scorer's judgment based on use-case-specific evidence, safety, and effect sizes.
Every dimension is evaluated on a 1–5 scale, and the baseline (1) is subtracted before weighting. A perfect intervention with zero downsides contributes zero penalty rather than a residual floor, so top-tier scores are actually reachable.
EV = Upside − Downside
EV = 3.000 − 2.231 = 0.769
Formula v2.0 maps EV = 0 to score 5.0. Above neutral, EV = +4.00 reaches 10.0; below neutral, EV = −5.36 reaches 0.0. Both sides use the full 5-point half-scale.
Score = 5 + (0.769 / 4.00) × 5 = 6.0 / 10